Although our observations suggest that the use of FDG-PET/CT in small, cN0 HER2+ breast cancer could result in upstaging in a subset of patients (7.7 %), its impact on nodal involvement after NAST remains uncertain. This evidence concerns the gene ERBB2 and breast cancer.